Enhanced Medium Chain Triglyceride Compositions for Brain Energy Deficiency Conditions

The present invention relates to improved medium chain triglyceride (MCT) compositions with enhanced ratios, purities, and formulations for treating brain energy deficiency conditions and neurological disorders, providing faster, safer, and more efficient ketone and C10 fatty acid delivery.

The original patent disclosed MCT compositions for treating brain energy deficiency conditions, but had limitations in terms of MCT ratios, purities, and formulations, which restricted their efficacy and safety. The present invention addresses these limitations by providing optimized MCT compositions with controlled-release, high-purity, and bioavailability-enhanced formulations.

The inventive concept comprises MCT compositions with specific ratios of MCT-C8 to MCT-C10 (30:70 to 70:30 mol/mol), high purities (at least 98 mol %), and formulations that enhance bioavailability and provide sustained release of ketones and C10 fatty acids. The compositions can be administered in various forms, including controlled-release capsules, powders, and liquids. The inventive concept also includes methods for treating brain energy deficiency conditions, enhancing cognitive function, and preventing neurological disorders using these optimized MCT compositions.

The new claims introduce novel and non-obvious improvements over the original patent, including the use of controlled-release formulations, high-purity MCTs, and specific ratios of MCT-C8 to MCT-C10. These advancements provide faster, safer, and more efficient delivery of ketones and C10 fatty acids, making the inventive concept a significant improvement over the prior art.

Alternative embodiments of the inventive concept include using different MCT ratios, purities, and formulations, as well as combining MCTs with other nutrients or compounds to enhance their efficacy. Variations of the inventive concept could also include using different administration forms, such as injectables, transdermal patches, or oral tablets.

The inventive concept has significant commercial potential in the nutritional supplement and pharmaceutical industries, particularly in the areas of brain health, cognitive function, and neurological disorders. The market for MCT-based products is growing rapidly, and the present invention is well-positioned to capitalize on this trend.